Array BioPharma Inc. the National Comprehensive Cancer Network has updated their Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to include Braftovi in combination with Mektovi and an anti-EGFR antibody as a Category IIa treatment for patients with BRAFV600E-mutant metastatic colorectal cancer, after failure of one or two prior lines of therapy for metastatic disease.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
